Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,527 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol).
Malagola M, Turra A, Signorini L, Corbellini S, Polverelli N, Masina L, Del Fabro G, Lorenzotti S, Fumarola B, Farina M, Morello E, Radici V, Buttini EA, Colnaghi F, Bernardi S, Re F, Caruso A, Castelli F, Russo D. Malagola M, et al. Among authors: russo d. Front Oncol. 2022 Jun 17;12:874117. doi: 10.3389/fonc.2022.874117. eCollection 2022. Front Oncol. 2022. PMID: 35785189 Free PMC article.
Profile of toll-like receptors on peripheral blood cells in relation to acute graft-versus-host disease after allogeneic stem cell transplantation.
Skert C, Fogli M, Perucca S, Garrafa E, Fiorentini S, Filì C, Bergonzi C, Malagola M, Turra A, Colombi C, Cattina F, Alghisi E, Caruso A, Russo D. Skert C, et al. Among authors: russo d. Biol Blood Marrow Transplant. 2013 Feb;19(2):227-34. doi: 10.1016/j.bbmt.2012.09.013. Epub 2012 Sep 26. Biol Blood Marrow Transplant. 2013. PMID: 23022388 Free article.
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.
Filì C, Malagola M, Follo MY, Finelli C, Iacobucci I, Martinelli G, Cattina F, Clissa C, Candoni A, Fanin R, Gobbi M, Bocchia M, Defina M, Spedini P, Skert C, Manzoli L, Cocco L, Russo D. Filì C, et al. Among authors: russo d. Clin Cancer Res. 2013 Jun 15;19(12):3297-308. doi: 10.1158/1078-0432.CCR-12-3540. Epub 2013 Apr 17. Clin Cancer Res. 2013. PMID: 23596104 Clinical Trial.
PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization.
Rossi G, Skert C, Morello E, Almici C, Arcaini L, Basilico C, Cavalli L, Botto B, Castelli A, Pica G, Ripamonti F, Salvi F, Carella AM, Gaidano G, Levis A, Nosari A, Russo D, Vitolo U. Rossi G, et al. Among authors: russo d. Hematol Oncol. 2015 Sep;33(3):125-32. doi: 10.1002/hon.2148. Epub 2014 May 29. Hematol Oncol. 2015. PMID: 24890497
Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation.
Malagola M, Skert C, Ruggeri G, Turra A, Ribolla R, Cancelli V, Cattina F, Alghisi E, Bernardi S, Perucca S, Di Palma A, Borlenghi E, Pagani C, Rossi G, Caimi L, Russo D. Malagola M, et al. Among authors: russo d. Biomed Res Int. 2014;2014:123079. doi: 10.1155/2014/123079. Epub 2014 Aug 17. Biomed Res Int. 2014. PMID: 25202702 Free PMC article.
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.
Carlo-Stella C, Ricci F, Dalto S, Mazza R, Malagola M, Patriarca F, Viviani S, Russo D, Giordano L, Castagna L, Corradini P, Santoro A. Carlo-Stella C, et al. Among authors: russo d. Oncologist. 2015 Mar;20(3):323-8. doi: 10.1634/theoncologist.2014-0420. Epub 2015 Feb 10. Oncologist. 2015. PMID: 25669663 Free PMC article.
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
Malagola M, Skert C, Borlenghi E, Chiarini M, Cattaneo C, Morello E, Cancelli V, Cattina F, Cerqui E, Pagani C, Passi A, Ribolla R, Bernardi S, Giustini V, Lamorgese C, Ruggeri G, Imberti L, Caimi L, Russo D, Rossi G. Malagola M, et al. Among authors: russo d. Cancer Med. 2016 Feb;5(2):265-74. doi: 10.1002/cam4.593. Epub 2015 Dec 29. Cancer Med. 2016. PMID: 26715369 Free PMC article.
1,527 results